#Repost @iamchristinadiarcangelo with @use.repost ・・・ Affinity Bio Partners on Working with Zelira Therapeutics to Complete Enrolment for Diabetic Nerve Pain Drug Trial It’s an exciting time in the medical cannabis community as Zelira, a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, and Affinity Bio Partners, a leading, global clinical research organization, have completed enrollment for a diabetic nerve pain drug trial. The Institutional Review Board (IRB)-approved head-to-head trial read out is expected in Q1 of 2023. Two years in the making, the study’s clinical management, clinical trial site monitoring, subject recruitment, regulatory submissions and review and query of data have brought us to a pivotal point that could pave the way for how future clinical studies are conducted in the medical cannabis community. As someone who comes from traditional pharma and biotechnology industries, heading up a clinical study in the medical cannabis realm has been a significantly different, eye-opening and informative experience that reinforces the dire need for mainstream, medical cannabis education. #women #womensupportingwomen #womeninbiz #women-entrepreneurs #womenfounders #medicalcannabis #cbd #clinicalresearch #womensupportingwomen #creativeentrepreneur #businesswoman #businessmindset #womenwhohustle #clinicalresearch #patientadvocate #health #patient #momsofinstagram #cannabis #iamchristinadiarcangelo #femaleempowerment #femaleentrepreneur #book #publisher #authorsofinstagram #author #apple #podcast #iamchristinadiarcangelopodcastshow #wearethesame #clinicalresearch #education @cannabisindustryjournal Check out the full article: https://cannabisindustryjournal.com/column/first-pharma-vs-cannabis-clinical-trial-moves-forward/ (at New York, New York) https://www.instagram.com/p/Cl_ahPGOKbq/?igshid=NGJjMDIxMWI=